HPS Pharmacies wish to advise that Link Pharmaceuticals has given notice of an interruption to the supply of:
Apresoline® 20mg powder for injection
Aust R: 43190
The interruption to supply of Apresoline® 20mg powder for injection is not expected to be fully resolved before March 2015.
Whilst no alternative brands are registered in Australia, alternative medicines are identified in guidelines for the management of hypertensive disorders of pregnancy published on the website of the Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG).
HPS Pharmacies can offer intravenous labetalol for immediate supply to Category A, seriously ill patients, pending completion and forwarding of the Category A SAS form by the medical practitioner. Category B forms must be completed and approved by the TGA prior to any supply.
There is no concern regarding the safety of supplies of hydralazine hydrochloride powder for injection currently available in Australia. This notice does not apply to hydralazine hydrochloride oral tablets.
Please retain this notice in a prominent position, including in other related business units as a reminder for all staff members until supply returns to normal.
Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please do not hesitate to contact your pharmacist at HPS Pharmacies, or Link Pharmaceuticals on (02) 8401 9777.
Information regarding expected dates for supply may vary subject to delays which are out of our control. HPS Pharmacies does not accept responsibility for such changes but will endeavour to keep our clients updated as information is made available from drug manufacturers or wholesalers.